Melasma
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Li se yon kondisyon komen obsève nan fanm Azyatik nan kòmansman ane 40 yo. Lezyon an sèk nan foto a se pi pre lentigo olye ke melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Dènyèman, low-fluence Q-switched Nd:YAG (LFQSNY) lazè te vin popilè pou trete melasma, espesyalman nan pwovens Lazi. Rezime etid divès te difisil, men LFQSNY sanble jeneralman efikas ak san danje pou melasma konpare ak terapi tradisyonèl yo. Sepandan, gen kèk ka ipopigmantasyon takte yo te rapòte kòm yon efè segondè nan LFQSNY, petèt akòz gwo enèji lazè. Itilizasyon agresif nan LFQSNY ka mennen tou nan ipèpigmantasyon nan enflamasyon, patikilyèman nan ton po pi fonse.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Pwoblèm pigmantasyon yo souvan jwenn nan swen prensipal. Kalite komen nan maladi hyperpigmentation gen ladan post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Melasma pa ka rezoud ak tretman lazè pou yon sèten peryòd tan, kòm li se yon maladi nan ki pigman yo kontinyèlman pwodwi. Asid tranxenemik ede amelyore diminye pigmantasyon an.
○ Tretman
Nan kèk peyi (tankou Japon, Kore di), asid tranexamic oral ki disponib sou kontwa an epi li efikas. Krèm melasma a ak asid tranexamic ak asid azelaik ka pasyèlman itil.
Hydroquinone ka itilize lokalman pou tretman ipèpigmantasyon, men FDA te sispann pwodwi OTC ki gen idrokinòn apati 2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma